Europe approves Eylea for treating macular edema secondary to CRVO

Article

 

Tarrytown, NY-Regeneron Pharmaceuticals Inc. announced that Eylea (aflibercept) injection has been approved by the European Commission for the treatment of visual impairment due to macular edema secondary to Central Retinal Vein Occlusion (CRVO).

Eylea is a recombinant fusion protein, consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration. Eylea acts as a soluble decoy receptor that binds VEGF-A and placental growth factor (PlGF) and thereby can inhibit the binding and activation of their cognate VEGF receptors.

George D. Yancopoulos, MD, PhD, chief scientific officer and president of Regeneron, said, “Our Phase III studies showed that Eylea improved visual outcomes significantly in macular edema following CRVO. This additional approval of Eylea is great news for patients in Europe suffering from macular edema following CRVO.”

Eylea was approved in the United States for treatment of neovascular (wet) age-related macular degeneration (AMD) in November 2011, and for macular edema following CRVO in September 2012. Eylea has also been approved in Europe, Japan, Australia, and in several other countries for use in wet AMD and in selected countries in South America for macular edema following CRVO.

Bayer HealthCare and Regeneron are collaborating on the global development of Eylea. Regeneron maintains exclusive rights to Eylea in the United States. Bayer HealthCare licensed the exclusive marketing rights outside the United States, where the companies share equally the profits from sales of Eylea, except for Japan where Regeneron receives a royalty on net sales.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Patricia Buehler, MD, MPH, at ASCRS 2025
Brett Bielory, MD, at ASCRS 2025
At ASCRS 2025, Alex Hacopian, MD, shares information from his presentation on next-gen presbyopia-correcting intraocular lenses.
Rhue and Canto-Sims talk the value of contact lens patients, financial insights, and key benefits of implementing a contact lens management system.
Eva Kim, MD, shares visual outcomes of EVO implantable collamer lens in patients with low to moderate myopia
Drs Brianna Rhue and Diana Canto-Sims discuss the benefits of implementing a contact lens management system that can help improve lens sales at your practice.
Dr Ashley Wallace Tucker speaks on the Myopia Management Navigator.
Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.
Arkansas Optometric Association legislative cochairs Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD, discuss their involvement in their bill and provide context for its relevance.
Elise Kramer, OD, FAAO, FSLS, describes her take on a multidisciplinary approach to dry eye
© 2025 MJH Life Sciences

All rights reserved.